TPTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TPTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Turning Point Therapeutics's Stock Based Compensation for the three months ended in Jun. 2022 was $17.31 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2022 was $60.38 Mil.
The historical data trend for Turning Point Therapeutics's Stock Based Compensation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turning Point Therapeutics Annual Data | |||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||
Stock Based Compensation | 0.34 | 1.15 | 12.71 | 64.16 | 58.56 |
Turning Point Therapeutics Quarterly Data | |||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Stock Based Compensation | Get a 7-Day Free Trial | 13.30 | 13.79 | 14.19 | 15.09 | 17.31 |
Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.38 Mil.
Thank you for viewing the detailed overview of Turning Point Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.
Paolo Tombesi | officer: EVP & Chief Financial Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Steve M Sabus | officer: SVP & Chief Commercial Officer | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brian Sun | officer: SVP & General Counsel | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 |
Mohammad Hirmand | officer: EVP and Chief Medical Officer | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Athena Countouriotis | director, officer: President & CEO | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Siegfried Reich | officer: EVP & Chief Scientific Officer | 10505 ROSELLE STREET SAN DIEGO CA 92121 |
Andrew John Partridge | officer: EVP & Chief Commercial Officer | C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109 |
Annette North | officer: EVP, General Counsel & Secty. | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Mark J Alles | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Van Hoose Kyri K. | officer: Principal Accounting Officer | C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Barbara W. Bodem | director | C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Brian Lee Baker | officer: VP of Finance and Admin. | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121 |
Yi Larson | officer: EVP & Chief Financial Officer | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Jingrong Jean Cui | director, 10 percent owner, officer: Chief Scientific Officer | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121 |
Simeon George | director | 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428 |
From GuruFocus
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By PRNewswire PRNewswire • 07-06-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By PurpleRose PurpleRose • 07-14-2022
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire PRNewswire • 07-10-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By PurpleRose PurpleRose • 07-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.